ALLR Allarity Therapeutics Inc
5,068
$0.76
$0.0067
(0.87%)
| Watchers | 5,068 |
| 52-Wk Low | $0.71 |
| 52-Wk High | $366.40 |
| Market Cap | $1.75M |
| Volume | 4.01M |
| 52-Wk High | $366.40 |
| 52-Wk Low | $0.71 |
Why Is Nano-Cap Allarity Therapeutics Stock Trading Up On Thursday?Benzinga • 7 days ago
Allarity Therapeutics halts Phase 2 trial, citing compelling early results and plans for regulatory advancement. CEO Thomas Jensen affirms strategic shift. ALLR shares surge 38%.
read more...
Share to Feed
Allarity Therapeutics, Inc. (NASDAQ:ALLR - Free Report) shares are scheduled to reverse split on the morning of Tuesday, April 9th. The 1-20 reverse split was announced on Tuesday, April 9th. The...
Boston (April 4, 2024) Allarity Therapeutics, Inc. ( Allarity or the Company ) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments...
Allarity Therapeutics, Inc. (NASDAQ:ALLR - Get Free Report) saw a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 614,300 shares, a...
Allarity Therapeutics, Inc. (NASDAQ:ALLR - Get Free Report) shares traded down 3.8% on Thursday . The stock traded as low as $0.29 and last traded at $0.30. 351,333 shares were traded during trading...
The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development Further development of...
Boston (March 25, 2024) Allarity Therapeutics, Inc. ( Allarity or the Company ) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments...
Leadership Changes Led by Appointment of Co-Founder Thomas Jensen as Interim CEO and Jeremy Graff, Ph.D., former Eli Lilly Executive, as Executive AdvisorReduced Net Loss from Operations by 50% and...
Boston (February 28, 2024) Allarity Therapeutics, Inc. ( Allarity or the Company ) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments...
Allarity Therapeutics, Inc. (NASDAQ:ALLR Get Free Report) saw a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 673,000...